Stayble Therapeutics presents positive interim data from ongoing Phase 2b study
Stayble Therapeutics AB (”Stayble” or the ”Company”) is currently conducting a phase 2b study with the drug candidate STA363. The Company now presents positive interim data with established safety and tolerability as well as lower dispersion in pain measurements when analyzing now available blinded data from the six-month follow-up in the study."The fact that we once again can present positive interim data and now from around 100 patients, which is the inclusion goal in the study, is a very important milestone in our development. The positive interim results demonstrate a well-planned study